U.S. markets open in 29 minutes
  • S&P Futures

    3,851.75
    +42.50 (+1.12%)
     
  • Dow Futures

    31,261.00
    +349.00 (+1.13%)
     
  • Nasdaq Futures

    13,063.50
    +152.50 (+1.18%)
     
  • Russell 2000 Futures

    2,240.10
    +40.90 (+1.86%)
     
  • Crude Oil

    62.02
    +0.52 (+0.85%)
     
  • Gold

    1,735.60
    +6.80 (+0.39%)
     
  • Silver

    27.00
    +0.56 (+2.12%)
     
  • dólar/euro

    1.2057
    -0.0031 (-0.25%)
     
  • 10-Yr Bond

    1.4380
    -0.0220 (-1.51%)
     
  • Vix

    24.81
    -4.08 (-14.12%)
     
  • dólar/libra

    1.3944
    +0.0021 (+0.15%)
     
  • yen/dólar

    106.6210
    +0.1190 (+0.11%)
     
  • BTC-USD

    48,002.74
    +3,130.88 (+6.98%)
     
  • CMC Crypto 200

    963.86
    +30.72 (+3.29%)
     
  • FTSE 100

    6,564.77
    +81.34 (+1.25%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW ORLEANS, Jan. 29, 2021 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI).

Kahn Swick & Foti, LLC ("KSF") - - not all law firms are created equal.  Visit www.ksfcounsel.com to learn more about KSF. (PRNewsfoto/Kahn Swick & Foti, LLC)
Kahn Swick & Foti, LLC ("KSF") - - not all law firms are created equal. Visit www.ksfcounsel.com to learn more about KSF. (PRNewsfoto/Kahn Swick & Foti, LLC)

On February 22, 2019, the Federal Drug Administration ("FDA") reported serious flaws in the New Drug Application and the underlying clinical trial data for the Company's drug, selinexor. Specifically, the FDA detailed that the Company's clinical trials demonstrated a history of toxicity and limited efficacy findings due to its trial designs and faulted the Company for violating pre-specified trial protocols and guidance when attempting to use "real-world" data observations to bolster its case for approval.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws, which remains ongoing.

KSF's investigation is focusing on whether Karyopharm's officers and/or directors breached their fiduciary duties to Karyopharm's shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Karyopharm shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-kpti/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/karyopharm-investigation-initiated-by-former-louisiana-attorney-general--kahn-swick--foti-llc-investigates-the-officers-and-directors-of-karyopharm-therapeutics-inc---kpti-301218425.html

SOURCE Kahn Swick & Foti, LLC